Cargando…
Non-invasive Urine Test for Molecular Classification of Clinical Significance in Newly Diagnosed Prostate Cancer Patients
Objective: To avoid over-treatment of low-risk prostate cancer patients, it is important to identify clinically significant and insignificant cancer for treatment decision-making. However, no accurate test is currently available. Methods: To address this unmet medical need, we developed a novel gene...
Autores principales: | Guo, Jinan, Zhang, Xuhui, Xia, Taolin, Johnson, Heather, Feng, Xiaoyan, Simoulis, Athanasios, Wu, Alan H. B., Li, Fei, Tan, Wanlong, Johnson, Allan, Dizeyi, Nishtman, Abrahamsson, Per-Anders, Kenner, Lukas, Xiao, Kefeng, Zhang, Heqiu, Chen, Lingwu, Zou, Chang, Persson, Jenny L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476767/ https://www.ncbi.nlm.nih.gov/pubmed/34595190 http://dx.doi.org/10.3389/fmed.2021.721554 |
Ejemplares similares
-
A 23‐Gene Classifier urine test for prostate cancer prognosis
por: Guo, Jinan, et al.
Publicado: (2021) -
Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up
por: Johnson, Heather, et al.
Publicado: (2020) -
Establishing a Urine-Based Biomarker Assay for Prostate Cancer Risk Stratification
por: Guo, Jinan, et al.
Publicado: (2020) -
Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells
por: Sarwar, Martuza, et al.
Publicado: (2016) -
The functional interlink between AR and MMP9/VEGF signaling axis is mediated through PIP5K1α/pAKT in prostate cancer
por: Larsson, Per, et al.
Publicado: (2019)